Payment overview · 2025
General Payments
$18,554.08
107 reported records · 33 companies
Healthcare provider profile · identity verified
William Long, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CHARLOTTE, NC · NPI 1992778906
Verified facts
What the public records show
CMS Open Payments records show William Long, M.D. received $18,554.08 in general payments during 2025 across 107 reported records.
Neurocrine BioSciences, Inc. accounted for 89.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ingrezza, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Enbrel by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 569 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16,680.70 | 89.9% | 17 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $205.09 | 1.1% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $154.28 | 0.8% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $147.17 | 0.8% | 11 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $134.92 | 0.7% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $126.12 | 0.7% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.55 | 0.6% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $87.83 | 0.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.07 | 0.4% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $71.71 | 0.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $68.14 | 0.4% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $62.80 | 0.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.13 | 0.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.76 | 0.3% | 3 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $46.74 | 0.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $40.15 | 0.2% | 2 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $37.67 | 0.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.44 | 0.2% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.74 | 0.2% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $35.26 | 0.2% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $34.10 | 0.2% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $29.16 | 0.2% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $28.74 | 0.1% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $26.42 | 0.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.90 | 0.1% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $21.99 | 0.1% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $18.52 | 0.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.87 | 0.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.39 | 0.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.86 | 0.1% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $15.59 | 0.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.99 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.28 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,639.00 | 3 |
| Consulting Fee | $6,375.00 | 1 |
| Travel and Lodging | $2,310.20 | 5 |
| Food and Beverage | $2,229.88 | 98 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16,680.70 | 17 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $205.09 | 10 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $205.09 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $147.17 | 11 | 2025 |
Source payment records
|
|||||
| TRYVIO Normalized: tryvio |
Drug | IDORSIA PHARMACEUTICALS US INC | $134.92 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $126.12 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $126.04 | 7 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $71.71 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $71.64 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $68.14 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $67.85 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $66.96 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $62.80 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.13 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.13 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.10 | 2 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $44.86 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.97 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $40.15 | 2 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $37.67 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.27 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $35.26 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $29.16 | 1 | 2025 |
Source payment records
|
|||||
| Persona Normalized: persona |
Device | Zimmer Biomet Holdings, Inc. | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 192 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 101 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 104 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
101 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
192 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
192 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
93 | 13 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
569 | 91 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1036 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 747 | 153 |
| Eliquis | Apixaban | 569 | 91 |
| Gabapentin | Gabapentin | 527 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 484 | 96 |
| Furosemide | Furosemide | 479 | 97 |
| Losartan Potassium | Losartan Potassium | 453 | 74 |
| Omeprazole | Omeprazole | 391 | 91 |
| Trazodone Hcl | Trazodone Hcl | 369 | 97 |
| Mirtazapine | Mirtazapine | 329 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 327 | 60 |
| Potassium Chloride | Potassium Chloride | 316 | 63 |
| Lisinopril | Lisinopril | 304 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 304 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 296 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 293 | 72 |
| Alprazolam | Alprazolam | 286 | 35 |
| Carvedilol | Carvedilol | 270 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 60 |
| Sertraline Hcl | Sertraline Hcl | 255 | 58 |
| Prednisone | Prednisone | 234 | 90 |
| Metformin Hcl | Metformin Hcl | 220 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 215 | 42 |
| Jardiance | Empagliflozin | 192 | 37 |
| Latanoprost | Latanoprost | 179 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 177 | 25 |
| Levetiracetam | Levetiracetam | 175 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 170 | 39 |
| Levofloxacin | Levofloxacin | 156 | 96 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 148 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 28 |
| Donepezil Hcl | Donepezil Hcl | 139 | 32 |
| Meloxicam | Meloxicam | 139 | 26 |
| Spironolactone | Spironolactone | 139 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 126 | 36 |
| Xarelto | Rivaroxaban | 125 | 20 |
| Lorazepam | Lorazepam | 118 | 32 |
| Divalproex Sodium | Divalproex Sodium | 116 | 30 |
| Finasteride | Finasteride | 116 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 115 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 22 |
| Allopurinol | Allopurinol | 111 | 28 |
| Famotidine | Famotidine | 111 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 110 | 11 |
| Ozempic | Semaglutide | 104 | 18 |
| Linzess | Linaclotide | 101 | 23 |
| Buspirone Hcl | Buspirone Hcl | 100 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 100 | 24 |
| Simvastatin | Simvastatin | 96 | 20 |
| Torsemide | Torsemide | 96 | 26 |
| Clonidine Hcl | Clonidine Hcl | 94 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 93 | 23 |
| Memantine Hcl | Memantine Hcl | 93 | 14 |
| Trulicity | Dulaglutide | 93 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 92 | 39 |
| Baclofen | Baclofen | 90 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 90 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 17 |
| Myrbetriq | Mirabegron | 88 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 87 | 42 |
| Ezetimibe | Ezetimibe | 83 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 80 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 32 |
| Risperidone | Risperidone | 77 | 12 |
| Farxiga | Dapagliflozin Propanediol | 74 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 72 | 29 |
| Midodrine Hcl | Midodrine Hcl | 71 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 27 |
| Lamotrigine | Lamotrigine | 67 | suppressed |
| Pregabalin | Pregabalin | 66 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 64 | 16 |
| Estradiol | Estradiol | 63 | 14 |
| Azithromycin | Azithromycin | 61 | 40 |
| Cephalexin | Cephalexin | 61 | 42 |
| Montelukast Sodium | Montelukast Sodium | 60 | 15 |
| Entresto | Sacubitril/Valsartan | 58 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | suppressed |
| Budesonide | Budesonide | 55 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 53 | suppressed |
| Sucralfate | Sucralfate | 53 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 34 |
| Fluconazole | Fluconazole | 46 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 45 | suppressed |
| Digoxin | Digoxin | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | 19 |
| Nystatin | Nystatin | 42 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 24 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 39 | 39 |
| Ceftriaxone | Ceftriaxone Sodium | 39 | 26 |
| Labetalol Hcl | Labetalol Hcl | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 12 |
| Carbamazepine | Carbamazepine | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 12 |
| Mupirocin | Mupirocin | 35 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 34 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | 16 |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Meropenem | Meropenem | 32 | suppressed |
| Nyamyc | Nystatin | 32 | 12 |
| Topiramate | Topiramate | 32 | suppressed |
| Amantadine | Amantadine Hcl | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 22 |
| Gemtesa | Vibegron | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 13 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 28 | suppressed |
| Phenytoin | Phenytoin | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 21 |
| Glipizide | Glipizide | 27 | suppressed |
| Azathioprine | Azathioprine | 26 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 26 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Sulfasalazine | Sulfasalazine | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 25 | 13 |
| Cefdinir | Cefdinir | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Insulin Lispro | Insulin Lispro | 25 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Zonisamide | Zonisamide | 25 | suppressed |
| Alphagan P | Brimonidine Tartrate | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 15 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Enulose | Lactulose | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | 11 |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Auryxia | Ferric Citrate | 18 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Neupro | Rotigotine | 17 | suppressed |
| Travoprost | Travoprost | 17 | suppressed |
| Atovaquone | Atovaquone | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 15 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Rytary | Carbidopa/Levodopa | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Enbrel | Etanercept | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18,554.08 · 107 records | Neurocrine BioSciences, Inc. | APLENZIN, AREXVY, AUSTEDO XR, BREZTRI, CAPLYTA, CAPVAXIVE, ETERNA, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, IBSRELA, INGREZZA, INNOVAMATRIX AC, INSPIRE, JARDIANCE, JATENZO, Kerendia, Korlym, LEQVIO, LINZESS, Leqembi, MOUNJARO, NALOCET, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PRECIVITYAD2, PROLATE, Persona, REPATHA, REXULTI, SHINGRIX, SMARTVEST, TANLOR, TMS NeuroHealth Centers Inc., TRYVIO, VYVGART HYTRULO, WELLBUTRIN, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error